Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1275 • ACR Convergence 2020
Unexpected Changes in Physical and Psychological Measures Among Georgia Lupus Patients During the Early Weeks of the COVID-19 Pandemic in the United States, March 30–April 21, 2020
S. Sam Lim¹, Kristina Theis², Charmayne Dunlop-Thomas¹, Gaobin Bao¹, Charles Helmick², Caroline Gordon³ and Cristina Drenkard⁴, ¹Emory University, Atlanta, GA, ²Centers for Disease Control and Prevention, Atlanta, GA, ³University of Birmingham, Birmingham, England, United Kingdom, ⁴Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA
Background/Purpose: An infectious disease outbreak can lead to negative physical and psychological consequences in the general public, as shown by the early COVID-19 pandemic, through…
Abstract Number: 1291 • ACR Convergence 2020
Depressed Symptomatology Persists over Time in the Majority of Systemic Lupus Erythematosus Patients and Is Independent of Disease Activity
Sara Kellahan¹, Xinliang Huang¹, Daphne Lew², Hong Xian³, Seth Eisen¹ and Alfred Kim⁴, ¹Division of Rheumatology, Washington University in St. Louis School of Medicine, St. Louis, ²Division of Biostatistics, Washington University in St. Louis School of Medicine, St. Louis, ³Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, St. Louis, ⁴Washington University School of Medicine, St. Louis, MO
Background/Purpose: Depression is a prevalent (24-30%) and significant comorbidity in patients with systemic lupus erythematosus (SLE) (1). As the American College of Rheumatology (ACR) classifies…
Abstract Number: 1461 • ACR Convergence 2020
Implementation, Feasibility and Acceptability of Take Charge, an Email Series to Increase Knowledge of Lupus Self-Management Skills
Karin Tse¹, Mary Crimmings², Mike Donnelly², Reid Dossinger², Lauren Metelski² and Latifa Boyce², ¹Lupus Foundation of America, DC, WA, ²Lupus Foundation of America, WASHINGTON, DC
Background/Purpose: The Lupus Foundation of America developed and launched an educational email series, Take Charge, to provide people with lupus educational information, tools and resources…
Abstract Number: 1565 • ACR Convergence 2020
Joint Cartilage Damage Evaluated by Ultrasound in Patients with Systemic Lupus Erythematosus
Takehisa Ogura¹, Ayako Hirata², Yuki Inoue², Takaharu Katagiri², Yuto Takakura² and Hideto Kameda³, ¹Division of Rheumatology, Department of Internal Medicine, Toho University, Meguro-ku, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University, Tokyo, Japan, ³Toho University, Tokyo, Japan
Background/Purpose: Arthritis in systemic lupus erythematosus (SLE) is typically non-erosive, although some patients with SLE show erosive destruction or Jaccoud’s arthropathy. Previously we have confirmed…
Abstract Number: 1676 • ACR Convergence 2020
Neuropsychiatric Involvement in Juvenile-onset Systemic Lupus Erythematosus (JSLE): Data from the UK JSLE Cohort Study
Teresa Giani¹, Eve Smith², Rolando Cimaz³, Michael Beresford⁴ and Christian Hedrich², ¹AOU Meyer, Florence, Italy, ²University of Liverpool, Liverpool, United Kingdom, ³ASST Gaetano Pini-CTO Institute and Università degli Studi di Milano, Milan, Italy, Milan, Italy, ⁴Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is a rare autoimmune/inflammatory disease, accounting for up to 20% of SLE cases. Though clinically similar to adult-onset disease,…
Abstract Number: 1787 • ACR Convergence 2020
Differences in Chromatin Architecture Between Treatment Naïve Pediatric and Adult Lupus Patients
Joyce Hui-Yuen¹, Frank Jenkins², Kaiyu Jiang³, Susan Malkiel⁴, Betty Diamond⁴ and James Jarvis⁵, ¹Northwell LIJ Health System, Manhasset, NY, ²Northwell Health, Manhasset, ³University at Buffalo, Buffalo, NY, ⁴Northwell Health, Manhasset, NY, ⁵University at Buffalo Jacobs School of Medicine, Buffalo, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is possibly triggered by gene-environment interactions. We showed most of the SLE haplotypes encompass genomic regions enriched for epigenetic marks…
Abstract Number: 1806 • ACR Convergence 2020
The Association of Interferon-α with Kynurenine/Tryptophan Pathway Activation in Systemic Lupus Erythematosus
Erik Anderson¹, Ying Jin², Sara Goodwin², Julien Roeser³, Richard Furie⁴, Cynthia Aranow⁵, Bruce Volpe⁵, Betty Diamond⁶ and Meggan Mackay⁷, ¹Feinstein Institutes for Medical Research, New York, NY, ²Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, ³Charles River Laboratories, South San Francisco, CA, ⁴Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵Feinstein Institutes for Medical Research, Manhasset, NY, ⁶Northwell Health, Manhasset, NY, ⁷Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Type I IFN contributes to SLE pathogenesis and stimulates the kynurenine/tryptophan (KYN/TRP) pathway, producing elevated quinolinic acid (QA) levels relative to kynurenic acid (KA)…
Abstract Number: 1823 • ACR Convergence 2020
Mycophenolate Mofetil for Systemic Lupus Erythematosus: Our 20-year Experience
Michael Trevisonno¹, Alexander Hall¹, Cristina Sorrento¹ and Ellen M Ginzler², ¹State University of New York Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Health Sciences University, Brooklyn
Background/Purpose: Mycophenolate Mofetil (MMF) has been long used in the treatment of systemic lupus Erythematosus (SLE). Despite its proven effectiveness, particularly in the treatment of…
Abstract Number: 1840 • ACR Convergence 2020
A Novel Biomarker Identifies Systemic Lupus Erythematous (SLE) Patients Who Benefit from Obexelimab (XmAb®5871) Treatment
Ying Ding¹, Debra Zack¹, Bart Burington¹, Allen Yang¹, Joan Merrill², Judith James³, John Desjarlais¹, Raphael Clynes¹ and Joel Guthridge⁴, ¹Xencor Inc, Monrovia, CA, ²New York University, New York, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: We previously reported Phase 2 SLE trial results for obexelimab, a CD19-targeted FcγRIIb engager that suppresses B-cell activation [1]. The primary endpoint, which measured…
Abstract Number: 0244 • ACR Convergence 2020
What Are the Early versus Late Predictors for Systemic Lupus Erythematosus (SLE) Diagnosis?
Yiting Wang¹, Kirsten Lum², Karen Costenbader³, Grace Wang⁴, Jennifer Lofland⁵, Dominik Naessens⁶, Yihan Zhao⁷, Kourtney Davis⁸ and Chetan Karyekar⁹, ¹Janssen Research & Development, LLC, Newark, DE, ²Janssen Pharm Technology - Data Sciences and Data Management, Horsham, PA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Janssen Pharmaceuticals, Horsham, ⁵Janssen Global Market Access, horsham, PA, ⁶Jassen Global Market Access, Beerse, Belgium, ⁷Janssen Pharm Technology - Data Sciences and Data Management, Horsham, ⁸Janssen R&D, LLC, Titusville, NJ, ⁹Janssen Global Services, LLC, Horsham, PA
Background/Purpose: SLE is clinically heterogenous and its diagnosis is often difficult or delayed. The length of time from symptom onset or from when patients seek…
Abstract Number: 0260 • ACR Convergence 2020
Does Higher Quality of Care in SLE Improve Quality of Life?
Shilpa Arora¹, Patricia Katz², Jinoos Yazdany³, Joel Block¹, Edward Yelin⁴ and Meenakshi Jolly⁵, ¹Rush University Medical Center, Chicago, IL, ²University of California, San Francisco, Novato, CA, ³University of California, San Francisco, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵Rush University, Chicago, IL
Background/Purpose: Disease activity, damage and quality of life (QOL) are core outcomes in Systemic lupus erythematosus (SLE). ER visits and hospital admissions (non-routine health care…
Abstract Number: 0277 • ACR Convergence 2020
Incidence and Time to Classification of Systemic Lupus Erythematosus by Three Different Classification Criteria
Ali Duarte-Garcia¹, Mehmet Hocaoglu², Shirley-Ann Osei-Onomah³, Jesse Dabit¹, Rachel Giblon¹ and Cynthia Crowson⁴, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Classification criteria are standardized definitions required to identify well defined cohorts of patients for research. In practice they are also used as a framework…
Abstract Number: 0295 • ACR Convergence 2020
CCL3L3–null Status May Predispose to Systemic Lupus Erythematosus and Non-scarring Alopecia
Eunyoung Lee¹, Young-Ho Kim², Hye Won Sim², Eun-Kyung Kang², Yoon-Ho Won², Esther Park², Yeong-Wook Song³ and Kyeong-Man Hong², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²National Cancer Center, Ilsan, Kyonggi-do, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Seoul, Korea, Republic of Korea
Background/Purpose: The correlation between the copy number variation of CCL3L1 and susceptibility to systemic lupus erythematosus (SLE), rheumatoid arthritis, Kawasaki disease, and HIV infection has…
Abstract Number: 0441 • ACR Convergence 2020
Use of an Integrated Care Management Program to Uncover and Address Social Determinants of Health for Individuals with Lupus
Kreager Taber¹, Jessica Williams¹, Weixing Huang², Katherine McLaughlin¹, Christine Vogeli³, Rebecca Cunningham¹, Lisa Wichmann¹ and Candace Feldman⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ³Massachusetts General Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston
Background/Purpose: The burden of systemic lupus erythematosus (SLE) falls disproportionately on racial/ethnic minorities and individuals of lower socioeconomic status who often receive fragmented, inconsistent care.…
Abstract Number: 0582 • ACR Convergence 2020
Mortality and Cost of Hospitalization: Do Hospitals Caring for More SLE Patients Perform Better?
Christine Anastasiou¹, Laura Trupin¹, Patricia Katz², Zara Izadi³, Milena Gianfrancesco¹, Gabriela Schmajuk⁴ and Jinoos Yazdany⁵, ¹University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, Novato, CA, ³University of California San Francisco, San Francisco, CA, ⁴University of California, San Francisco, Atherton, CA, ⁵UCSF, San Francisco, CA
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) have an increased risk of hospitalization throughout their lifetime, potentially leading to higher patient mortality and healthcare costs.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].